Business Wire - October 27, 2009
Three new partnerships are reshaping the competitive environment in HIV. Most notably, Tibotec/Johnson & Johnson is linking up with Gilead to combine their Phase III drug rilpivirine with Truvada to create a new gold standard fixed dose combination for treatment-na ve patients. Addressing Atripla's shortcomings, Datamonitor expects this product to dominate the market.
Scope
* In-depth analysis of Phase II and III clinical development compounds and comprehensive overview of Phase I drugs
* An overview of the key companies involved in the HIV pipeline, including an analysis of the new corporate alliances
* The epidemiology dynamics of HIV in the six major markets are discussed along with unmet needs that have evolved from the prolonged use of HAART
* Sales forecasts over the next 10 years for the each of the late-stage drugs
Highlights of this title
Advances in antiretroviral therapy have addressed the two big unmet medical needs, resistance and safety. Convenience is the new frontier, pointing towards a bright future for cross-class fixed-dose combination, notably Gilead's Quad Pill and Gilead's and Johnson & Johnson's Truvada/rilpivirine combination.
Gilead's two new cross-class fixed dose combinations offer only moderate medical progress, but their added convenience compared with single ingredient formulations will cement the company's market leadership and reduce the market opportunity for single-ingredient formulations.
Abbott's monopoly in protease inhibitor boosting agents is nearing its end. At least three companies have pharmacokinetic enhancers with potentially improved safety profiles in clinical development, hopefully enabling the creation of more co-formulated brands
Key reasons to purchase this title
* Understand the constantly evolving market dynamics of antiretroviral drugs in view of corporate alliances, co-formulations and generic entry
* Learn about the changing unmet needs of patients and the extent to which pipeline drugs are addressing these issues
* Evaluate the forecast of key pipeline antiretroviral drugs to 2018, taking into account key launch dates, patent expirations and other factors
Key Topics Covered:
* Overview
* Catalyst
* Summary
* Pipeline Overview and Dynamics
* HIV - Market Potential
* R&D Approach
* Pipeline Analysis & Forecasts: Nucleoside Reverse Transcriptase Inhibitors
* Pipeline Analysis & Forecasts: Protease Inhibitors
* Pipeline Analysis & Forecasts: Non-Nucleoside Reverse Transcriptase Inhibitors
* Pipeline Analysis & Forecasts: Entry Inhibitors
* Pipeline Analysis & Forecasts: Integrase inhibitors
* Pipeline Analysis & Forecasts: Cross-Class Fixed-Dose Combinations
* Innovative Early-Stage Approaches
* APPENDIX
* List of Tables
* List of Figures
For more information visit http://www.researchandmarkets.com/research/f9e8fd/pipeline_insight
Source: Datamonitor
Contacts
Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
091027
BW091033
Copyright © 2009 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .